Roche at EBCC 2018
The 11th European Breast Cancer Conference provided a multidisciplinary setting for breast cancer specialists from around the world.
Mar 20, 2018 | Breast Cancer EBCC 2018
Mar 21, 2018 | Breast Cancer EBCC 2018
The open-label, multinational, multicenter, Phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients (pts) with HER2-positive early breast cancer (EBC) or metastatic breast cancer (MBC): Pooled analysis of safety data from the UmbHER1 program